rethinkPeptides Search
Menu
Home / Research library
Study breakdown

Long-Term PRRT for Neuroendocrine Tumors in Japan: Efficacy and Safety Confirmed

RPEP-154462026Kobayashi, Noritoshi; Ono, Hiroaki; Okubo, Naoki; Akahoshi, Keiichi; Kudo, Atsushi; Ban, Daisuke; Ichikawa, Yasushi
evidence
The takeaway

Peptide receptor radionuclide therapy (PRRT) with 177Lu-oxodotreotide showed long-term efficacy and acceptable safety in Japanese NET patients, confirming global PRRT results in the Japanese population.

Japan confirms PRRT

Long-term Japanese data confirms that peptide-targeted radiation therapy (PRRT) effectively controls neuroendocrine tumors with acceptable safety

What the researchers found

177Lu-oxodotreotide PRRT: long-term efficacy and acceptable safety confirmed in Japanese NET patients, consistent with global PRRT data.

Why it matters

Japanese patients need local long-term safety data for treatment confidence. This confirms PRRT's role in NET management in Japan.

How the study worked

Long-term efficacy and safety assessment of PRRT with 177Lu-oxodotreotide in Japanese NET patients.

What this study cannot tell us

Japanese population-specific data. Sample size in full paper.

How to read the evidence

Long-term efficacy/safety study in Japanese population.

When this study was published

Published in 2025.

The bigger picture

PRRT represents the most successful clinical application of peptide-targeted radionuclide therapy worldwide.

Questions still open

  • How does Japanese PRRT response compare to Western populations?
  • Should PRRT be first-line or reserved for advanced NETs in Japan?
  • Would combination PRRT + chemotherapy improve Japanese NET outcomes?

Common questions

What is PRRT?
Peptide receptor radionuclide therapy attaches radioactive atoms to peptides that target neuroendocrine tumor cells, delivering radiation directly to the cancer while sparing healthy tissue.
Does PRRT work for Japanese patients?
Yes. This long-term study confirmed PRRT is effective and safe in Japanese NET patients, consistent with results seen worldwide.

Read the original research

Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study.

Annals of nuclear medicine

View on PubMed ↗Publisher’s paper ↗

Citation

Kobayashi, Noritoshi; Ono, Hiroaki; Okubo, Naoki; Akahoshi, Keiichi; Kudo, Atsushi; Ban, Daisuke; Ichikawa, Yasushi. (2026). Long-term efficacy and safety of peptide receptor radionuclide therapy in Japanese patients with unresectable neuroendocrine tumor: extension of the Japanese phase I and phase I/II study.. Annals of nuclear medicine. https://doi.org/10.1007/s12149-026-02169-1